造血干细胞移植治疗难治性血液病临床研究(附117例报告)  

Clinical study of HSCT in treatment in refractory hematological diseases

作　　者：黄宁[1] 葛林阜[1] 刘希民[1] 马焕文[1] 孔立新[1] 郭鹏[1] 

机构地区：[1]济南军区总医院,山东济南250031

出　　处：《山东医药》2005年第16期1-3,共3页Shandong Medical Journal

摘　　要：目的探讨造血干细胞移植(HSCT)治疗难治性血液病的效果。方法117例患者中,重型再生障碍性贫血(SAA)6例,慢性髓细胞白血病(CML)23例,急性白血病(AL)35例,多发性骨髓瘤(MM)4例,骨髓增生异常综合征(MDS)1例,恶性淋巴瘤48例。接受自体骨髓/外周血HSCT58例,同基因骨髓/外周血HSCT2例,异基因骨髓/外周血HSCT53例,脐带血HSCT4例。结果随访(62±57)个月,至今仍存活84例(71.8%),死亡33例(28.2%);死因为未成功植入2例(1.7%),宿主排斥移植物反应(HVG)1例(0.9%),感染6例(5.1%),急性移植物抗宿主病(GVHD)2例(1.7%),复发22例(18.8%)。结论HSCT能治愈常规方法难以治疗的血液病;AL、MM、MDS及有骨髓浸润的恶性淋巴瘤患者自体HSCT的复发率较异体HSCT明显增高。Objective To explore the efficacy of hematopoietic stem cell transplantation(HSCT) in treatment in refractory hematological diseases.Methods The clinic data of 117 cases of hematopoietic stem cell transplantation was analyzed.Of them,6 were severe aplastic anemia(SAA),23 chronic myeloid leukemia(CML),35 acute leukemia (AL),4 multiple myeloma(MM),1 myelodysplastic syndrome,48 malignant lymphoma.All of them were treated by HSCT.Results 84 patients were alive with a median follow-up of (62±57) months,33 cases (28.2%) died:2 cases were engrafted,1 case died of HVG,6 cases died of infection,2 cases died of aGVHD,22 cases died of relapse.Conclusions HSCT for refractory hematological diseases is safe and effective.The relapse rate of auto-HSCT in AL,MM,MDS and malignant lymphoma is higher than allo-HSCT.

关 键 词：难治性血液病 造血干细胞移植治疗 临床研究 重型再生障碍性贫血 骨髓增生异常综合征 急性移植物抗宿主病 慢性髓细胞白血病 恶性淋巴瘤 多发性骨髓瘤 HSCT 急性白血病 异基因骨髓 外周血 自体骨髓 常规方法 骨髓浸润 同基因 

分 类 号：R733[医药卫生—肿瘤] R714.5[医药卫生—临床医学]